The Post-Aromatase Battlefield: Breaking Down Eli Lilly's Inluriyo Strategy, Companion Diagnostic Moats, and the Oral SERD Market Shift
DDDr. Dereck Mush, MD, MBA
Sep 22
Eli Lilly and Company
Global drugmaker behind Inluriyo, the oral SERD approved with Verzenio for ESR1 mutated breast cancer.
What they do
Eli Lilly is a global pharmaceutical company with a deep oncology franchise. In September 2026 the FDA approved Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for ER positive, HER2 negative, ESR1 mutated advanced breast cancer after endocrine therapy, based on the phase 3 EMBER-3 trial.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Targeted oncology
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Indianapolis, United States
- Region
- North America
- Founded
- 1876
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
DDDr. Dereck Mush, MD, MBA
Jul 16
The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
DDDr. Dereck Mush, MD, MBA
Sep 14
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
DDDr. Dereck Mush, MD, MBA
Sep 16